Compare Shell PLC (SHEL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs Zoetis Inc — how do they compare? Shell PLC trades at $95.97 (market cap $271.50B), while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Shell PLC is far larger — about 9× Zoetis Inc's market cap, and Shell PLC pays the higher dividend (3.27%). Which is the better fit depends on your goals.
| SHEL | ZTS | |
|---|---|---|
Market Cap | $271.50B | $30.29B |
Sector | Energy | Health |
52-Week High | $95.60 | $150.61 |
52-Week Low | $70.31 | $71.91 |
Enterprise Value | $313.20B | $37.86B |
Dividend Yield | 3.27% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $95.32, up 2.55% on the day and near its record high, driven by strong crude oil prices and positive earnings momentum with recent quarterly beats. The stock shows a bullish technical outlook, supported by moving averages, while fundamentals reflect solid profitability with an 8.76% net margin and attractive valuation metrics like a P/E of 10.54. Recent developments include strategic acquisitions in deepwater projects and retail expansion, enhancing growth prospects.
The outlook for SHEL remains positive, with analyst consensus favoring a buy rating and a $101 price target, implying upside potential. Key opportunities include oil price tailwinds and operational efficiency, though risks involve revenue volatility from energy markets and geopolitical tensions, as highlighted by recent news. Investors should weigh robust cash flows against cyclical industry headwinds.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
